Market Overview

Gossamer Bio Announces Appointment of Luisa Salter-Cid, Ph.D. as Chief Scientific Officer

Share:

Gossamer Bio, Inc. ("Gossamer Bio") today announced that Luisa
Salter-Cid, Ph.D. will join its executive management team as Chief
Scientific Officer. Dr. Salter-Cid will lead the company's research and
preclinical development efforts.

"Luisa is an exceptional scientist whose immunology background focused
on drug discovery and translation is truly impressive, and I am thrilled
to be reunited with her," said Sheila Gujrathi, M.D., Chief Executive
Officer of Gossamer Bio. "Her collaboration and integration with
clinical development makes her the perfect addition at a critically
important time for Gossamer Bio. Luisa's track record of identifying and
developing differentiated assets in our core therapeutic areas will
bring great long-term value to our company."

"I am honored to lead the research and scientific efforts at Gossamer
Bio," said Dr. Salter-Cid. "The team and pipeline of innovative and
transformative medicines that Gossamer Bio has assembled are truly
exciting. I look forward to continuing to grow the portfolio and
advancing these novel therapies rapidly to the clinic for patients who
are suffering."

Dr. Salter-Cid brings to Gossamer Bio over 20 years of drug discovery
experience in the biotech and pharmaceutical industries. She spent the
last 13 years at Bristol Myers Squibb ("BMS") in increasing positions of
responsibility, including Vice President and Head of Immunology, small
molecule Immuno-Oncology and Genomics Discovery. In this position, she
oversaw several biology groups that focused on target validation and
development of innovative biologic and small-molecule therapeutics to
address significant unmet needs in autoimmune diseases and cancer.
During her time at BMS, Dr. Salter-Cid led teams that advanced more than
20 compounds into clinical development. She was also Chair of the
Immunoscience Target Science Team and a core member of Early
Development, Strategy and Licensing teams for both Immunology and
Immuno-Oncology. Additionally, she was the scientific lead on several of
BMS' acquisitions and licensing deals and sat on multiple Joint Research
Committees and Scientific Advisory Boards. Prior to joining BMS, she was
a Senior Project Leader at La Jolla Pharmaceuticals where she led
discovery projects. Dr. Salter-Cid also held positions at Genset Corp
and Johnson & Johnson. She is an author of over 70 publications and
patents and holds a Ph.D. in Immunology from the University of Miami.

About Gossamer Bio:

Gossamer Bio is a San Diego-based biopharmaceutical company focused on
discovering, developing, and commercializing immunology-based
therapeutics in the autoimmune, allergy/inflammation and immuno-oncology
disease areas. Our goal is to improve the lives of patients suffering
from disease. We aim to create a business that allows value creation and
capture at the individual asset level, long-term sustainability, and
continuity. More information can be found at www.gossamerbio.com.

View Comments and Join the Discussion!